JavaScript is disabled for your browser. Some features of this site may not work without it.

    Listar

    Todo RIUMAComunidades & ColeccionesPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentrosEsta colecciónPor fecha de publicaciónAutoresTítulosMateriasTipo de publicaciónCentros

    Mi cuenta

    AccederRegistro

    Estadísticas

    Ver Estadísticas de uso

    DE INTERÉS

    Datos de investigaciónPolítica institucional UMAPolítica de RIUMAPolitica de datos de investigación en RIUMASHERPA/RoMEODulcinea
    Preguntas frecuentesManual de usoDerechos de autorContacto/Sugerencias
    Ver ítem 
    •   RIUMA Principal
    • Investigación
    • Farmacología y Pediatría - (FP)
    • FP - Artículos
    • Ver ítem
    •   RIUMA Principal
    • Investigación
    • Farmacología y Pediatría - (FP)
    • FP - Artículos
    • Ver ítem

    Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with Severe Cutaneous Adverse Reactions

    • Autor
      Villanueva-Paz, Marina; Niu, Hao; Segovia-Zafra, Antonio; Medina-Caliz, Inmaculada; Sanabria-Cabrera, Judith; [et al.]
    • Fecha
      2021-11-15
    • Editorial/Editor
      MDPI
    • Palabras clave
      Ensayo clínico; Hígado -- Enfermedades
    • Resumen
      Drug-induced liver injury (DILI) encompasses the unexpected damage that drugs can cause to the liver. DILI may develop in the context of an immunoallergic syndrome with cutaneous manifes- tations, which are sometimes severe (SCARs). Nevirapine, allopurinol, anti-epileptics, sulfonamides, and antibiotics are the most frequent culprit drugs for DILI associated with SCARs. Interestingly, alleles HLA-B*58:01 and HLA-A*31:01 are associated with both adverse reactions. However, there is no consensus about the criteria used for the characterization of liver injury in this context, and the different thresholds for DILI definition make it difficult to gain insight into this complex disorder. Moreover, current limitations when evaluating causality in patients with DILI associated with SCARs are related to the plethora of causality assessment methods and the lack of consensual complementary tools. Finally, the management of this condition encompasses the treatment of liver and skin injury. Although the use of immunomodulant agents is accepted for SCARs, their role in treating liver injury remains controversial. Further randomized clinical trials are needed to test their efficacy and safety to address this complex entity. Therefore, this review aims to identify the current gaps in the definition, diagnosis, prognosis, and management of DILI associated with SCARs, proposing different strategies to fill in these gaps.
    • URI
      https://hdl.handle.net/10630/23503
    • DOI
      https://dx.doi.org/10.3390/jcm10225317
    • Compartir
      RefworksMendeley
    Mostrar el registro completo del ítem
    Ficheros
    Critical Review of Gaps in the Diagnosis and Management of Drug-Induced Liver Injury Associated with SCARs.pdf (2.128Mb)
    Colecciones
    • FP - Artículos

    Estadísticas

    Ver Estadísticas de uso
    Academic Search
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
     

     

    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA
    REPOSITORIO INSTITUCIONAL UNIVERSIDAD DE MÁLAGA